Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01641003|
Recruitment Status : Unknown
Verified July 2012 by Rambam Health Care Campus.
Recruitment status was: Not yet recruiting
First Posted : July 16, 2012
Last Update Posted : July 16, 2012
- to evaluate insoluble fibrinogen particles (iFP), as a tool for harvesting, growing and transferring attachment-dependent cancer stem cells and comparing it to the standard method ( coated plate) .
- to evaluate whether using iFP for growing CSC can yield better results of isolating and enriching CSCs from fresh tumors than other conventional methods
|Condition or disease|
|Malignant Neoplasm of Breast Glioma Pancreatic Cancer|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||Isolation and Characterization of Cancer Stem Cells Using iFP Technique|
|Study Start Date :||July 2012|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||June 2015|
Fresh tumor specimen
Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
- Cancer stem cells percentage [ Time Frame: 24 months ]Evaluation of CSCs and non-CSCs population by using several surface markers. For glioma and pancreas, CSC are defined as CD133 positive. For breast carcinoma CSCs are identified as CD44+/CD24-/Low. Percentage of CSCs will be measured for comparing the yield of the methods using iFP and the standard method.
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01641003
|Contact: FADI - MIZYED, Dr.||+firstname.lastname@example.org|
|Rambam Health Care Campus||Not yet recruiting|
|Contact: FADI - MIZYED, Dr. +972-4-8543162|
|Principal Investigator: FADI - MIZYED, MD.|
|Principal Investigator:||FADI - MIZYED, Dr.||Rambam Health Care Campus|